These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25293770)

  • 21. Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing.
    Dubovsky JA; Chappell DL; Harrington BK; Agrawal K; Andritsos LA; Flynn JM; Jones JA; Paulaitis ME; Bolon B; Johnson AJ; Byrd JC; Muthusamy N
    Blood; 2013 Nov; 122(19):3308-16. PubMed ID: 24009233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
    Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
    Suljagic M; Longo PG; Bennardo S; Perlas E; Leone G; Laurenti L; Efremov DG
    Blood; 2010 Dec; 116(23):4894-905. PubMed ID: 20716772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.
    Gordiienko I; Shlapatska L; Kholodniuk V; Sklyarenko L; Gluzman DF; Clark EA; Sidorenko SP
    PLoS One; 2017; 12(10):e0185940. PubMed ID: 28982149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B cell receptor signaling in chronic lymphocytic leukemia.
    Burger JA; Chiorazzi N
    Trends Immunol; 2013 Dec; 34(12):592-601. PubMed ID: 23928062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment.
    Shen Y; Crassini K; Sandhu S; Fatima N; Christopherson RI; Mulligan SP; Best OG
    Leuk Lymphoma; 2019 Jul; 60(7):1632-1643. PubMed ID: 30648436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Ponader S; Chen SS; Buggy JJ; Balakrishnan K; Gandhi V; Wierda WG; Keating MJ; O'Brien S; Chiorazzi N; Burger JA
    Blood; 2012 Feb; 119(5):1182-9. PubMed ID: 22180443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B-cell antigen receptor expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia.
    Schmid VK; Khadour A; Ahmed N; Brandl C; Nitschke L; Rajewsky K; Jumaa H; Hobeika E
    Haematologica; 2022 Aug; 107(8):1796-1814. PubMed ID: 35021605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OSU-T315 and doxorubicin synergistically induce apoptosis via mitochondrial pathway in bladder cancer cells.
    Li Z; Ren D; Chen C; Sun L; Fang K
    Cell Biol Int; 2022 Oct; 46(10):1672-1681. PubMed ID: 35830716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase 8 activation.
    Plate JM
    Leuk Lymphoma; 2004 Aug; 45(8):1519-29. PubMed ID: 15370202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
    Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
    Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia.
    Seda V; Vojackova E; Ondrisova L; Kostalova L; Sharma S; Loja T; Mladonicka Pavlasova G; Zicha D; Kudlickova Peskova M; Krivanek J; Liskova K; Kren L; Benes V; Musilova Litzmanova K; Borsky M; Oppelt J; Verner J; Pospisilova S; Brychtova Y; Panovska A; Tan Z; Zhang S; Doubek M; Amruz Cerna K; Mayer J; Mraz M
    Blood; 2021 Sep; 138(9):758-772. PubMed ID: 33786575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
    Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.
    Holler C; Piñón JD; Denk U; Heyder C; Hofbauer S; Greil R; Egle A
    Blood; 2009 Mar; 113(12):2791-4. PubMed ID: 19168795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia.
    Ecker V; Stumpf M; Brandmeier L; Neumayer T; Pfeuffer L; Engleitner T; Ringshausen I; Nelson N; Jücker M; Wanninger S; Zenz T; Wendtner C; Manske K; Steiger K; Rad R; Müschen M; Ruland J; Buchner M
    Nat Commun; 2021 Jun; 12(1):3526. PubMed ID: 34112805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.
    Efanov A; Zanesi N; Nazaryan N; Santanam U; Palamarchuk A; Croce CM; Pekarsky Y
    Leukemia; 2010 May; 24(5):970-5. PubMed ID: 20357824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.
    Frezzato F; Raggi F; Martini V; Severin F; Trimarco V; Visentin A; Scomazzon E; Accordi B; Bresolin S; Piazza F; Facco M; Basso G; Semenzato G; Trentin L
    Int J Cancer; 2019 Dec; 145(11):3089-3100. PubMed ID: 31044428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.
    Guo A; Lu P; Lee J; Zhen C; Chiosis G; Wang YL
    Oncogene; 2017 Jun; 36(24):3441-3449. PubMed ID: 28114285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.
    Cuní S; Pérez-Aciego P; Pérez-Chacón G; Vargas JA; Sánchez A; Martín-Saavedra FM; Ballester S; García-Marco J; Jordá J; Durántez A
    Leukemia; 2004 Aug; 18(8):1391-400. PubMed ID: 15175625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.
    Lapalombella R; Sun Q; Williams K; Tangeman L; Jha S; Zhong Y; Goettl V; Mahoney E; Berglund C; Gupta S; Farmer A; Mani R; Johnson AJ; Lucas D; Mo X; Daelemans D; Sandanayaka V; Shechter S; McCauley D; Shacham S; Kauffman M; Chook YM; Byrd JC
    Blood; 2012 Nov; 120(23):4621-34. PubMed ID: 23034282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.